Step Ph
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
V-Bio VenturesVia a fund
PontifaxVia a fund
55 portfolio companies: Climb Bio, CadenSee, Crystalys Therapeutics - Passionate. Dedicated. We improve lives. and 52 more
Kurma PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Karen Smith: One year as CMO
This month marks a year since Dr Karen Smith joined Step Pharma as Chief Medical Officer. To mark the occasion, we sat down with Karen to talk about her reflections on her time at the Company so far, upcoming milestones for the business and where she sees
Read more
Report
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
Press Release St. Genis-Pouilly, France, 1 July 2026 Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncology His appointment will strengthen
Read more
Report
Step Pharma advances dencatistat into phase 2 clinical trial for essential thrombocythaemia
Press Release St. Genis-Pouilly, France, 17 June 2026 Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces that it has advanced dencatistat, the Company's first-in-class, highly selective, oral
Read more
Report
Philip Beer: Why essential thrombocythaemia treatment is overdue a revolution
Philip Beer, Chief Scientific Officer at Step Pharma, reflects on the myleproliferative neoplasms field, and specifically the treatment of essential thrombocythaemia, 16 years after completing his PhD in the subject: Plus ça change, plus c'est la même cho
Read more
Report
Step Pharma secures €2.5 million EIC grant to accelerate development of dencatistat for CTPS2 null gynaecological tumours
Press Release St. Genis-Pouilly, France, 19 February 2026 Blended finance award also includes up to €10 million in equity investment from the EIC Step Pharma's lead product, dencatistat, expected to begin evaluation in phase 1b expansion cohorts for CTPS2
Read more
Report
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
Press Release St. Genis-Pouilly, France, 28 October 2025 Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step
Read more
Report
Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
Press Release St. Genis-Pouilly, France, 21 October 2025 Session: AACR Project GENIE: Powering Drug Discovery Through an International Consortium' Presentation title: Using GENIE data to drive oncology target identification and drug development. Thursday
Read more
Report
Step Pharma announces first participant dosed in a phase 1b clinical trial of dencatistat for essential thrombocythaemia
Press Release St. Genis-Pouilly, France, 2 September 2025 Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announced that the first participant has been dosed with its lead asset dencatistat in a phas
Read more
Report
Step Pharma receives US FDA orphan drug designation for dencatistat in T-Cell lymphoma
Press Release St. Genis-Pouilly, France, 22 May 2025 Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD)
Read more
Report